31 results about "IL1 Inhibitor" patented technology

Methods and compositions generating and using an interleukin-1 receptor antagonist (IL-1ra)-rich solution. Methods for generating and isolating interleukin-1 receptor antagonist include incubating adipose tissue and / or adipocytes with polyacrylamide beads to produce interleukin-1 receptor antagonist. The interleukin-1 receptor antagonist is isolated from the polyacrylamide beads to obtain the solution rich in interleukin-1 receptor antagonist. Methods for treating a site of inflammation in a patient include administering to the site of inflammation the solution rich in interleukin-1 receptor antagonist.

The present disclosure provides a fusion protein comprising IL-1 receptor antagonist fused to a hybrid Fc. Particularly the present disclosure relates to a fusion protein comprising IL-1 receptor antagonist fused to a human immunoglobulin hybrid Fc fragment. In one embodiment, the hybrid Fc fragment comprises IgD and IgG4. Also provided is a pharmaceutical composition comprising the present fusion protein, which are useful for treating autoimmune disease including rheumatoid arthritis, inflammatory bowel disease (Crohn's disease, ulcerative colitis), psoriasis and diabetes and the like. The present fusion protein with excellent efficacy and reduced side effects is qualified for clinical development as therapeutic antibodies to treat autoimmune disease.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Cytoplasmic aspartate aminotransferase, soluble Tumor necrosis factor receptor superfamily member 5, soluble CD40 Ligand, soluble C-X-C Motif chemokine 16, S100-A12, Eotaxin, soluble E-selectin, Fibronectin, Granulocyte colony-stimulating factor, Granulocyte-macrophage colony-stimulating factor, Heparin-binding growth factor 2, soluble Hepatocyte growth factor receptor, Interleukin-1 receptor antagonist, Interleukin-1 beta, Interleukin-10, Interleukin-15, Interleukin-3, Myeloperoxidase, Nidogen-1, soluble Oxidized low-density lipoprotein receptor 1, Pappalysin-1, soluble P-selectin glycoprotein ligand 1, Antileukoproteinase, soluble Kit ligand, Tissue inhibitor of metalloproteinase 1, Tissue inhibitor of metalloproteinase 2, soluble Tumor necrosis factor, soluble Vascular cell adhesion molecule 1, and Vascular endothelial growth factor A as diagnostic and prognostic biomarkers in renal injuries.

Apparatus and methods for producing interleukin-1 receptor antagonist and / or other prophylatically or therapeutically effective protein. Blood is obtained from a patient with a conventional syringe and then introduced into dual luer lock centrifuge tube. The dual luer lock centrifuge tube is provided with beads that are coated with a silanized coating. The container is then incubated and centrifuged. Subsequent to the incubation and the centrifugation, the serum containing autologous therapeutically active protein, such as IL-1Ra, in the container is withdrawn through the luer lock of the container, and injected back into the patient.

Methods and compositions generating and using an interleukin-1 receptor antagonist (IL-1ra)-rich solution. Methods for generating and isolating interleukin-1 receptor antagonist include incubating a liquid volume of white blood cells and platelets with polyacrylamide beads to produce interleukin-1 receptor antagonist. The interleukin-1 receptor antagonist is isolated from the polyacrylamide beads to obtain the solution rich in interleukin-1 receptor antagonist. Methods for treating a site of inflammation in a patient include administering to the site of inflammation the solution rich in interleukin-1 receptor antagonist.

Substances that inhibit the action of the members of the IL-1β / NF-κB pathway can be used for protecting and preserving β-cell mass and function in prediabetic and diabetic type 2 patients. Specifically, the present invention relates to the use of an Interleukin 1 receptor antagonist (IL-1Ra) and / or pyrrolidinedithiocarbamate (PDTC) for the treatment or prophylaxis of type 2 diabetes, as well as a method for the treatment of type 2 diabetes.

The present invention relates to uses of interleukin-1 receptor antagonist (IL-1Ra) in promoting bone marrow regeneration, increasing peripheral white blood cells, and increasing platelet levels in subjects if administered prior to treatment with chemotherapeutic agents. Thus, particular embodiments of the invention are directed to uses of IL-1Ra as an adjuvant or ancillary therapy to alleviate the hematopoietic toxicities associated with chemotherapy.

The invention provides a amalgamation albumen of serum albumin and interleukin 1 receptor antagonist, comprising human serum albumin HAS, peptide joint and human interleukin1 receptor antagonist IL1ra, wherein the peptide joint is 0-20 aminophenol long and exists between human HSA and human IL1ra, the construct is [GlyGlyGlyGlyser]<n>, n represents an integer from 0 to 4. The amalgamation albumen is obtained by constructing recombination pichia cell line, inducing expression of recombination amalgamation albumen in a growth culture medium and purifying. The amalgamation albumen, on the basis of original vivo and vitro biology function, reduces the clearance of IL1ra in vivo, prolongs the half-life of IL1ra in vivo, decreases dose and ejection frequency, make the maximum treat action, reduces the potential side effect of IL1ra or toxicity, improves safety and tolerance, is substantial an aid to treat moderate and bad rheumatoid arthritis, and can be used in the preparation of interleukin receptor antagonist.

The invention relates to an adenoviral-based biological delivery and expression system for use in the treatment or prevention of osteoathritis in human or mammalian joints by long-term inducible gene expression of human or mammalian interleukin-1 receptor antagonist (Il-1Ra) in synovial cells, comprising a helper-dependent adenoviral vector containing a nucleic acid sequence encoding for human or mammalian interleukin-1 receptor antagonist (Il-1Ra), left and right inverted terminal repeats (L ITR and R ITR), the adenoviral packaging signal and non-viral, non-coding stuffer nucleic acid sequences, wherein the expression of the human or mammalian interleukin-1 receptor antagonist (Il-1Ra) gene within synovial cells is regulated by an inflammation-inducible promoter.

The invention discloses an expression system of fusion protein from human serum albumin and interleukin-1 receptor antagonist. The expression system comprises a host cell and an expression vector transferred into the same. The expression vector comprises a first expression vector with an inserted fusion protein gene and a second expression vector with an inserted protein disulfide isomerase gene.The fusion protein gene comprises the human serum albumin and the interleukin-1 receptor antagonist. The host cell is Pichia pastoris GS115. The co-expression host of PDI (protein disulfide isomerase) and IGH (immunoglobulin heavy) is established, and expression index of the IGH is evidently increased. The PDI is expressed intracellularly, the IGH secretory expression is subjected to extracellular secretory expression, and accordingly no newly generated other proteins occur when concentration of the IGH in collected medium supernate increases.

A method of diagnosing tuberculosis (TB) is provided. The method comprises the steps of: detecting a panel of at least four biomarkers selected from the group consisting of complement C3, complement factor H, alpha-2-macroglobulin, loaded Lipoprotein (APO)‑A1, Apolipoprotein APO‑CIII, Apolipoprotein APO‑E, Prealbumin Interferon (IFN)‑γ, Interferon (IFN)‑α2, Interferon Inducible Protein (IP) ‑10, Tumor necrosis factor (TNF)‑α, epidermal growth factor (EGF), macrophage inflammatory protein (MIP)‑1β, soluble CD40 ligand (sCD40L), transforming growth factor (TGF)‑α, vascular endothelial growth factor (VEGF), interleukin 1 receptor antagonist (IL‑1ra), matrix metalloproteinase (MMP)‑2, matrix metalloproteinase (MMP)‑9, binding globulin, c‑reactive protein (CRP), serum amyloid Protein A (SAA), procalcitonin (PCT), ferritin, tissue plasminogen activator (TPA), fibrinogen, and serum amyloid A (SAA). A panel may include more than four of the above-listed biomarkers, such as five, six, seven, or even more of the above-listed biomarkers. Apparatus for carrying out the method are also provided.

The invention discloses a recombinant human interleukin-1 receptor antagonist in-situ gel, which comprises a recombinant human interleukin-1 receptor antagonist and an in-situ gel material, wherein the in-situ gel material is one or more of a temperature-sensitive in-situ gel material, a pH-sensitive in-situ gel material and an ionic strength-sensitive in-situ gel material. The in-situ gel is flowable liquid at room temperature, has the advantages of easy access (injection, eye drop, nasal drop, spray, lung inhalation and the like), accurate dosage, and capacities of forming high-viscosity hardly flowing gel in short time when contacting tissues, prolonging the residence time in the tissues, increasing the medicament adsorption and fully exerting medicinal effects. The in-situ gel has theadvantages of adhesiveness, slow release, and capacities of greatly improving the medicinal bioavailability and achieving possible sustained-release long-acting effect.

The invention discloses a formula of a medicament for treating non-infectious ocular inflammations, and inhibiting the corneal neovascularization and the anti-rejection reaction generated after corneal grafting. Through the selection of an isotonizing agent and a buffering agent and the addition of an antiseptic agent, a release microsphere preparation, a recombinant human interleukin-8 receptor antagonist and a chemokine-like factors 1 (CKLF1), the activity of a recombinant human interleukin-1 receptor antagonist is enhanced, and the retention time thereof is extended. In the invention, the problem that in the prior art, because of having a high environmental requirement on the outside, the existing recombinant human interleukin-1 receptor antagonist is easy to inactivate is solved; and through adding the recombinant human interleukin-8 receptor antagonist and the chemokine-like factors 1 (CKLF1) into the medicament, a synergistic effect is generated among the recombinant human interleukin-8 receptor antagonist, the chemokine-like factors 1 (CKLF1) and the recombinant human interleukin-1 receptor antagonist, thereby reducing the dosage of the medicament.

The invention discloses a method for detecting the biological activity of recombinant human interleukin-1 receptor antagonist eye drops. The method comprises the following steps: (1) preparing a standardized products solution; (2) preparing a solution for test products; (3) measuring absorbance, recording the measurement result, processing test data by a computer program or four parameter regression calculation method, and calculating the biological activity of a test product. The method for detecting the biological activity of recombinant human interleukin-1 receptor antagonist eye drops is simple to operate and easy for observation, has good linear relation, good repeatability and strong specificity, and provides an effective technological means for monitoring product quality.

This invention discloses a new interleukin-1 antagonist active both against IL-1 alpha and IL-1 beta , a new DNA sequence encoding the Il-1 antagonist and the method for obtaining a IL-1 antagonist by the recombinant DNA technique; it is also described the prophylactic, therapeutic and diagnostic use of such new IL-1 antagonist in pathologies deriving from the IL-1 production.